ARTICLE

Volume 11,Issue 2

Cite this article
8
Citations
18
Views
26 February 2026

Analysis of the Effects of Amisulpride on Negative Symptoms and Cognitive Function in Patients with Schizophrenia Dependent on Benzodiazepines

Guoping Liu*
Show Less
1 New Campus of the Third People's Hospital of Binhai County, Yancheng 224500, Jiangsu, China
APM 2026 , 11(2), 126–130; https://doi.org/10.18063/APM.v11i2.1402
© 2026 by the Author. Licensee Whioce Publishing, Singapore. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Abstract

 Objective: To explore the effect of amisulpride on improving negative symptoms and cognitive function in a special group of patients with benzodiazepine-dependent schizophrenia. Methods: 100 patients with benzodiazepine-dependent schizophrenia admitted to the hospital from May 2023 to May 2024 were randomly divided into 2 groups. The control group was treated with risperidone, and the observation group was treated with amisulpride. The treatment effects of the two groups of patients were compared. Results: After 4 and 8 weeks of treatment, the negative symptom scores of the observation group were lower than those of the control group, and the difference was statistically significant (P < 0.05). The cognitive function scores of the patients in the observation group were higher than those of the control group, and the difference was statistically significant (P < 0.05). Conclusion: After treatment with amisulpride in patients with schizophrenia who are dependent on benzodiazepines, the negative symptoms and cognitive function of the patients are significantly improved, and it is worthy of recommendation.

Keywords
Amisulpride
benzodiazepines
drug dependence
schizophrenia
negative symptoms
cognitive function
References

[1] Cai MX, 2024, Comparison of the Clinical Effects of Lurasidone and Amisulpride in the Treatment of Negative Symptoms of Schizophrenia. Clinical Rational Drug Use, 17(14): 66-68+75.

[2] Yang Y, Wu H, Wang JM, et al., 2024, Clinical Effects of Amisulpride and Olanzapine in the Treatment of Schizophrenia in the Acute Phase. Psychological Monthly, 19(05): 82-84+222.

[3] Lan MY, Lan XS, Lan RX, 2024, Analysis of the Efficacy and Safety of Amisulpride Tablets in the Treatment of Patients with Acute Attacks of Schizophrenia. Northern Pharmacy, 21(03): 151-153.

[4] Zou ZW, Zhu YT, Song SQ, 2023, Analysis of the Clinical Effect of Amisulpride in the Treatment of First-Episode Schizophrenia. Systems Medicine, 8(23): 78-80+84.

[5] Zhang TT, Chen Y, Li W, et al., 2023, Clinical Study on Amisulpride Combined with Cognitive Behavioral Treatment of Negative Symptoms and Depressive Symptoms in Patients with Schizophrenia. Journal of Aerospace Medicine, 34(11): 1337-1339.

[6] Xu H, Zhang MR, Cao Y, et al., 2022, Network Meta-analysis of the Effects of Second-Generation Antipsychotic Drugs on Metabolic Syndrome-Related Indicators in Schizophrenia Patients. Chinese Journal of New Drugs, 31(19): 1952-1961.

[7] Yi K, Chen WY, 2022, Effects of Amisulpride on Negative Symptoms and Cognitive Function in Patients with Benzodiazepine-Dependent Schizophrenia. Drug Evaluation, 19(06): 368-370.

Share
Back to top